Advertisement

The Scientist

» Big Pharma and developmental biology

Most Recent

image: Contributors

Contributors

By | April 1, 2015

Meet some of the people featured in the April 2015 issue of The Scientist.

0 Comments

image: From Many, One

From Many, One

By | April 1, 2015

Diverse mammals, including humans, have been found to carry distinct genomes in their cells. What does such genetic chimerism mean for health and disease?

4 Comments

image: Short, Strong Signals

Short, Strong Signals

By | March 25, 2015

Methylation increases both the activity and instability of the signaling protein Notch.

0 Comments

image: AbbVie Wins Bidding War for Cancer Drugmaker

AbbVie Wins Bidding War for Cancer Drugmaker

By | March 5, 2015

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

0 Comments

image: Pfizer to Acquire Hospira

Pfizer to Acquire Hospira

By | February 5, 2015

The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.

0 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Fertility Treatment Fallout

Fertility Treatment Fallout

By | January 1, 2015

Mouse offspring conceived by in vitro fertilization are metabolically different from naturally conceived mice.

7 Comments

image: Roche Buys Bioinformatics Firm

Roche Buys Bioinformatics Firm

By | December 22, 2014

The pharmaceutical giant will pay an undisclosed price to acquire Bina Technologies.

0 Comments

image: NIH Study Canceled

NIH Study Canceled

By | December 15, 2014

The National Institutes of Health shutters its initiative to track the health of 100,000 children through adulthood.

3 Comments

image: Merck Buys Cubist for $8.4B

Merck Buys Cubist for $8.4B

By | December 11, 2014

Hours after the pharmaceutical giant announced the acquisition, a federal judge invalidated key patents behind the antibiotic maker’s most lucrative product.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement